Functional Characterization of Leishmania Transporters

利什曼原虫转运蛋白的功能表征

基本信息

  • 批准号:
    7433317
  • 负责人:
  • 金额:
    $ 36.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1991
  • 资助国家:
    美国
  • 起止时间:
    1991-09-01 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objective of this proposal is to study the biological function of glucose transporters in the parasite Leishmania mexicana. Leishmania species cause disease in an estimated 12 million individuals worldwide and are a major public health problem. Identification of genes and proteins that serve essential functions for the parasite is critical for the identification of targets for development of novel drugs. Previous work has demonstrated that the glucose transporters of L. mexicana, integral membrane proteins that mediate the uptake of glucose and related hexose sugars, are essential in the amastigote stage of the life cycle that infects vertebrates and causes disease. Hence, this proposal will focus upon the biochemical functions of parasite glucose transporters and attempt to explain why they are essential for the disease causing stage of the parasite life cycle. The first aim will examine each of the 3 principal fates of glucose in the cell and determine which of them is/are impaired by when glucose transporters are genetically ablated by targeted gene deletion. These fates of glucose include: i) incorporation into glycoconjugates and complex carbohydrates, ii) metabolism via the pentose phosphate pathway to generate NADPH and ribose phosphate, and iii) metabolism via glycolysis. These experiments will establish which of these 3 pathways are affected by the inability of a glucose transporter null mutant to import hexoses and which of these deficiencies may contribute to the non-viability of this null mutant as amastigotes. The second aim will investigate the specific functions of the 3 glucose transporter isoforms GT1, GT2, and GT3. Null mutants in each of these genes will be prepared and their phenotypes assessed in both the promastigote and amastigote stages of the life cycle. These experiments will help elucidate distinct functions for each of the 3 glucose transporters expressed by this parasite. Overall, this proposal will provide a detailed biochemical and genetic dissection of glucose transporter function and the essential role of these permeases in the parasite life cycle.
描述(由申请人提供):本提案的目的是研究墨西哥利什曼原虫中葡萄糖转运蛋白的生物学功能。利什曼原虫在全世界造成约1200万人患病,是一个重大的公共卫生问题。鉴定为寄生虫提供基本功能的基因和蛋白质对于确定开发新药的靶点至关重要。先前的研究已经证明,L. mexicana的葡萄糖转运体,介导葡萄糖和相关己糖摄取的整体膜蛋白,在感染脊椎动物并导致疾病的生命周期的无尾线虫阶段是必不可少的。因此,本研究将重点关注寄生虫葡萄糖转运体的生化功能,并试图解释为什么它们在寄生虫生命周期的致病阶段是必不可少的。第一个目标是检查细胞中葡萄糖的三种主要命运,并确定当葡萄糖转运蛋白被靶向基因删除时,它们中的哪一种受到损害。葡萄糖的这些命运包括:1)结合到糖缀合物和复杂的碳水化合物中,2)通过戊糖磷酸途径代谢产生NADPH和磷酸核糖,3)通过糖酵解代谢。这些实验将确定这三种途径中的哪一种会受到葡萄糖转运蛋白零突变体无法输入己糖的影响,以及这些缺陷中的哪一种可能导致该零突变体作为无纺丝体无法生存。第二个目的是研究3种葡萄糖转运蛋白异构体GT1、GT2和GT3的具体功能。将制备这些基因的零突变体,并在生命周期的promastigote和amastigote阶段评估它们的表型。这些实验将有助于阐明这种寄生虫表达的3种葡萄糖转运蛋白中的每一种的不同功能。总之,这一提议将提供葡萄糖转运蛋白功能的详细生化和遗传学解剖,以及这些渗透物在寄生虫生命周期中的重要作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott M Landfear其他文献

Scott M Landfear的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott M Landfear', 18)}}的其他基金

Function and Trafficking of Flagellar Membrane Proteins in Leishmania mexicana
墨西哥利什曼原虫鞭毛膜蛋白的功能和运输
  • 批准号:
    10632896
  • 财政年份:
    2023
  • 资助金额:
    $ 36.67万
  • 项目类别:
Interdisciplinary Training in Microbial Pathogenesis and Immunology
微生物发病机制和免疫学跨学科培训
  • 批准号:
    10712455
  • 财政年份:
    2023
  • 资助金额:
    $ 36.67万
  • 项目类别:
The Neddylation Pathway in Leishmania donovani - A High Opportunity Target
杜氏利什曼原虫的 Neddylation 途径 - 高机会目标
  • 批准号:
    10349372
  • 财政年份:
    2021
  • 资助金额:
    $ 36.67万
  • 项目类别:
Development of Novel Natural Product Inspired Antileishmanial Drugs
受天然产物启发的新型抗利什曼药物的开发
  • 批准号:
    10225214
  • 财政年份:
    2021
  • 资助金额:
    $ 36.67万
  • 项目类别:
The Neddylation Pathway in Leishmania donovani - A High Opportunity Target
杜氏利什曼原虫的 Neddylation 途径 - 高机会目标
  • 批准号:
    10493446
  • 财政年份:
    2021
  • 资助金额:
    $ 36.67万
  • 项目类别:
Development of Novel Natural Product Inspired Antileishmanial Drugs
受天然产物启发的新型抗利什曼药物的开发
  • 批准号:
    10382455
  • 财政年份:
    2021
  • 资助金额:
    $ 36.67万
  • 项目类别:
Function of the Essential KHARON1 Protein in Bloodstream Form African Trypanosomes
非洲锥虫血流中必需的 KHARON1 蛋白的功能
  • 批准号:
    9226017
  • 财政年份:
    2016
  • 资助金额:
    $ 36.67万
  • 项目类别:
Function of the Essential KHARON1 Protein in Bloodstream Form African Trypanosomes
非洲锥虫血流中必需的 KHARON1 蛋白的功能
  • 批准号:
    9007963
  • 财政年份:
    2016
  • 资助金额:
    $ 36.67万
  • 项目类别:
Development of Drugs that Target the Malaria Hexose Transporter
开发针对疟疾己糖转运蛋白的药物
  • 批准号:
    8968767
  • 财政年份:
    2015
  • 资助金额:
    $ 36.67万
  • 项目类别:
Development of Drugs that Target the Malaria Hexose Transporter
开发针对疟疾己糖转运蛋白的药物
  • 批准号:
    9086222
  • 财政年份:
    2015
  • 资助金额:
    $ 36.67万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 36.67万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 36.67万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 36.67万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.67万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 36.67万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 36.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 36.67万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 36.67万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 36.67万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 36.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了